




PHARMACEUTICAL 2020

Organogenesis Holdings Inc.
Rank 223 of 358





RealRate

PHARMACEUTICAL 2020

Organogenesis Holdings Inc. Rank 223 of 358



The relative strengths and weaknesses of Organogenesis Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Organogenesis Holdings Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 98% points. The greatest weakness of Organogenesis Holdings Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 95% points.

The company's Economic Capital Ratio, given in the ranking table, is 29%, being 7.8% points below the market average of 36%.

Input Variable	Value in 1000 USD
Assets, Current	125,600
Cost of Goods Sold	75,948
Intangible Assets	46,336
Liabilities, Current	59,894
Liabilities, Non-Current	6,649
Other Assets	1,567
Other Compr. Net Income	0
Other Expenses	150
Other Liabilities	98,561
Other Net Income	-10,845
Other Revenues	260,981
Property and Equipment	47,184
Research and Development	14,799
Selling, General and Administrative Expense	199,693

Output Variable	Value in 1000 USD
Assets	220,687
Liabilities	165,104
Expenses	290,590
Revenues	260,981
Stockholders Equity	55,583
Net Income	-40,454
Comprehensive Net Income	-40,454
Economic Capital Ratio	29%